Current Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacogenomics) - Volume 10, Issue 2, 2012

Full text available.

Full text available.

Full text available.

Blended herbal medicines are used in China (traditional Chinese medicine, TCM), Japan (Kampo medicine) and many other countries around the world. Here, we critically examine the metabolomics studies to develop a systematic understanding of Kampo medicines based on multivariate analyses in the context of an integrated platform, combining current and traditional knowledge of blended herbal medicines with data-in Read More

Doping with testosterone is conventionally detected by urinary assay of the testosterone/epitestosterone (T/E) glucuronide ratio. This ratio is strongly associated with a deletion polymorphism in the UDP-glucuronosyltransferase (UGT) 2B17 gene. The metabolism of certain UGT specific drugs has been shown to be different in men and women. The objective of this study was to evaluate the impact of gender as well as hu Read More

Identifying novel molecular drug targets continues to be of prime interest in addressing the public health burden of breast cancer in both developed and developing countries alike. In this context, proteomics/pharmacoproteomics approaches offer a new dimension for personalized medicine. We have previously identified differentially expressed proteins with antigenic activity between SKBR3 (ER-, high HER2 expression) and MCF7 Read More

Stakeholders’ views are invaluable in the process of garnering the resources and infrastructure necessary for public health genomics research and introducing efficient communication mechanisms and appropriate ethical frameworks. This research is crucial as pharmacogenomics applications are advancing towards public health. In order to learn about the perceptions stakeholders have towards the relevance of genomics for p Read More

While the personalized medicine literature has hitherto focused on diseases in developed countries, little discussion has materialized on ways in which genomics can importantly remedy highly prevalent diseases in developing countries. This paper aims to address this important lacuna in the biomedical literature—what we refer to herein as “developing world genomics” that needs recognition as an emerging subspecialty of gl Read More

Despite the great advances made in the diagnosis and management of hepatocellular carcinoma (HCC), HCC still remains as the third leading cause of cancer-related mortality, with approximately 695,000 deaths per year. Seventy-eight percent of new cases are found in Asia, especially China, Taiwan and Hong Kong, while HCC incidence has been increasing in the United States and Europe over the past decade. Although Read More

A decade after Francis Collins, then Director of the Human Genome Project, stated that: “Genetic prediction of individual risks of disease and responsiveness to drugs will reach the medical mainstream in the next decade or so” the uptake of therapeutic strategies informed by pharmacogenomic tests, often termed personalised medicine, has been limited. Several recent developments have been suggested as Read More